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ABSTRACT: The loss of β-cell function and β-cell death are
key features of diabetes. A range of mechanisms are thought to
contribute to β-cell loss, including islet amyloid formation by
the neuropancreatic hormone amylin (islet amyloid polypep-
tide, IAPP). Islet amyloid deposition also contributes to the
failure of islet transplants. There are no therapeutic strategies
for the treatment or prevention of islet amyloidosis. Aspirin
and the nonsteroid anti-inflammatory drug (NSAID) ketoprofen, at clinically relevant doses, have been proposed to inhibit
amyloid formation by amylin and thus may hold promise for treatment of islet amyloidosis. These compounds are potentially
attractive given the importance of inflammation in islet amyloidosis and given the fact that there are no anti-islet amyloid agents
in the clinic. We show that aspirin, even in 20-fold excess, has no effect on the kinetics of amyloid formation by amylin as judged
by thioflavin-T binding, right angle light scattering, and transmission electron microscopy, nor does it alter the morphology of
resulting amyloid fibrils. Aspirin showed no ability to disaggregate preformed amylin amyloid fibrils under the conditions of these
studies, 25 °C and pH 7.4. Ketoprofen is similarly ineffective at inhibiting amylin amyloid formation. The compounds do,
however, interfere with circular dichroism- and Congo Red-based assays of amylin amyloid formation. This study highlights the
importance of using multiple methods to follow amyloid formation when screening inhibitors.
Type 2 diabetes has reached epidemic proportions, and it isnow recognized that β-cell death and β-cell dysfunction
play important roles in the disease.1 A range of mechanisms
contribute to β-cell loss and dysfunction in vivo, including
inflammation and the deposition of amyloid in the islets of
Langerhans.2−5 Rapid formation of amyloid also leads to islet
graft failure, whereas its prevention has been shown to prolong
graft survival and lead to improved glycemic control.6,7 The
neuropancreatic hormone amylin is responsible for islet
amyloid formation. Amylin plays a role in controlling food
intake, gastric emptying, and glucose homeostasis, but it
aggregates to form islet amyloid in type 2 diabetes. Amylin is
stored in the insulin secretory granule and is thus released in
response to insulin secretion.8
Analogues of human amylin that are less aggregation prone
than wild-type human amylin have been approved as an adjunct
to insulin therapy,9 but there is no treatment for islet
amyloidosis, and there are no approved therapeutic strategies
to prevent islet amyloid deposition. The search for inhibitors of
amyloid aggregation and amyloid formation is an active area of
research,10−17 but comparatively few anti-amylin amyloid
compounds have been developed, and the vast majority of
those are not drug-like. Recently, the intriguing possibility that
clinically relevant doses of aspirin and the nonsteroid anti-
inflammatory drug (NSAID) ketoprofen may inhibit amylin
amyloid formation and might disaggregate preformed amylin
amyloid fibrils has been raised.18 This could open very
attractive, inexpensive therapeutic approaches if the compounds
were indeed effective anti-amylin amyloid agents, particularly
because inflammation is believed to play a role in islet
amyloidosis toxicity and a central role in type-2 diabetes.19−24
Here, we critically examine the effects of aspirin and ketoprofen
on amylin amyloid formation and the effects of aspirin on
preformed amylin amyloid fibrils. Aspirin does not inhibit
amylin amyloid formation, even when added at 20-fold excess,
and is unable to disassemble preformed amylin amyloid.
Ketoprofen is similarly ineffective at inhibiting amyloid
formation. The reasons for the discrepancy with prior reports
are examined, and it is concluded that they are due to
interference of the compounds with the analytical assays used
and with the difficulty in analyzing small changes in circular
dichroism (CD) spectra. The implications for the testing of
amyloid inhibitors are discussed. The present study emphasizes
the necessity of employing multiple techniques to avoid false
positives or false negatives in inhibition assays.
Received: March 2, 2014
Accepted: May 16, 2014
Published: May 16, 2014
Articles
pubs.acs.org/acschemicalbiology
© 2014 American Chemical Society 1632 dx.doi.org/10.1021/cb500162w | ACS Chem. Biol. 2014, 9, 1632−1637
Terms of Use
■ RESULTS AND DISCUSSION
Mature, fully processed amylin is 37 residues in length, contains
a disulfide bond between residues 2 and 7, and has an amidated
C-terminus (Figure 1). We first examined the effects of aspirin
on the kinetics of amyloid formation using fluorescence-
detected thioflavin-T binding assays. This is the standard assay
in this field. Thioflavin-T is a small fluorescent dye that binds to
the cross β-structure of amyloid fibrils, presumably in the
surface grooves formed by the parallel β-sheets. Binding
constrains the conformation of the dye and relieves self-
quenching, resulting in an increase in quantum yield.25 Figure 2
displays the results of kinetic experiments conducted in the
presence of aspirin. The expected sigmoidal time course is
observed in the absence of aspirin, with a T50, defined as the
time required to reach half of the total signal change in the
thioflavin-T assay, of 20 h. Addition of aspirin, up to even a 20-
fold excess, had no detectable effect on the rate of amyloid
formation, as judged by the values of T50. The compound also
had no detectable effect on the final thioflavin-T intensity.
Thioflavin-T binding assays are indirect because they rely on
the binding of an extrinsic probe and can sometimes give
misleading results,26 but they do have the advantage that they
report on the kinetics of amylin amyloid formation in the
absence of conflicting factors. We also used transmission
electron microscopy (TEM) to monitor the effects of aspirin.
Aliquots were removed from each sample at the end of kinetic
experiments, blotted onto TEM grids, and imaged. Extensive
mats of fibrils were observed in the sample of amylin alone and
in all of the samples that contained aspirin.
Initial reports of the ability of aspirin to inhibit amylin
amyloid formation did not use thioflavin-T assays or TEM, but
rather used CD and Congo red binding assays. It is possible,
although unlikely, that thioflavin-T could displace aspirin from
amylin and interfere with its effects. This does not seem
plausible because thioflavin-T has no such effect on a wide
range of other inhibitors27,28 and does not bind to preamyloid
intermediates. Nonetheless, we also tested the effects of aspirin
in the absence of thioflavin-T using right angle light scattering
(RALS) and TEM. Similar aggregation curves are observed in
the presence and absence of a 20-fold excess of aspirin using
RALS (Figure 3). TEM of the samples reveals the presence of
dense mats of fibrils in each sample. Note that these samples
did not contain thioflavin-T.
We next examined the ability of aspirin to disaggregate
preformed amylin amyloid fibrils. Some, but not all, inhibitors
of amyloid formation have this property. We monitored
amyloid formation using thioflavin-T assays (Figure 4) and
then added a 20-fold excess of aspirin after amyloid formation
was complete and the reaction had reached the saturation
phase. Aliquots were removed for TEM analysis just before
addition of aspirin, immediately afterward, and 48 h later.
Addition of the compound did not perturb the thioflavin-T
time course; in contrast, compounds that disaggregate amyloid
fibrils lead to a decay in the thioflavin-T signal as a function of
time.10 The TEM images recorded before and after addition of
aspirin are very similar and reveal extensive deposits of amyloid
fibrils, confirming that the compound does not disaggregate
amylin amyloid (Figure 4B−D). In addition, CD spectra
recorded before and after the addition of aspirin have an
identical shape, consistent with a high degree of β-structure,
although there is a modest decrease in intensity. Furthermore,
no changes in the CD spectra are observed upon further
incubation of up to 12 h (Supporting Information). The CD
Figure 1. Primary sequence of human amylin and the structure of
aspirin and ketoprofen. Amylin contains a disulfide bridge between
residues 2 and 7, and the C-terminus is amidated.
Figure 2. Aspirin does not inhibit amyloid formation by human amylin. (A) Thioflavin-T fluorescence assays of the time course of amyloid
formation in the absence (black) and presence (red) of a 20-fold excess of aspirin. (B) TEM image of the sample of amylin without aspirin recorded
at the end of the kinetic experiment. (C) TEM image of the sample of amylin with a 20-fold excess aspirin recorded at the end of the kinetic
experiment. Scale bars represent 100 nm. Experiments were conducted at pH 7.4 and 25 °C in 20 mM Tris buffer with 0.25% DMSO (v/v) in the
absence of any fluorinated alcohol cosolvent. The concentration of amylin was 16 μM, and the concentration of aspirin was 320 μM.
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studies are fully consistent with thioflavin-T, TEM, and RALS
experiments.
The NSAID ketoprofen has also been proposed to be an
inhibitor of amylin amyloid formation, again on the basis of
Congo red assays and CD spectroscopy. We examined the
ability of the compound to inhibit amyloid formation by human
amylin using TEM to test its effect on amyloid formation
directly (Figure 5). TEM analysis revealed the presence of
extensive mats of amyloid fibrils in all samples, showing that the
compound is not an amylin amyloid inhibitor.
■ CONCLUSIONS
The data presented here show that aspirin and ketoprofen do
not inhibit amylin amyloid formation under the conditions
used, pH 7.4 and 25 °C. Why do the conclusions of this study
differ from previous work? The earlier studies used
trifluoroethanol (TFE) to promote amyloid formation. TFE
and hexafluoroisopropanol (HFIP) stabilize secondary struc-
ture of peptides, and even a modest amount of HFIP or TFE
can accelerate amyloid formation.29 The use of a nonaqueous
solvent to induce amyloid formation may contribute to the
different conclusions, but the methods used also play a role.
The previous study made use of CD and absorbance-detected
Congo red binding assays. The reported CD spectra are
different in the presence of high concentrations of aspirin;
however, the reported spectrum, even at the highest
concentration of aspirin, is not that of a random coil and has
a shape consistent with significant β-sheet intensity. In addition,
Figure 3. Aspirin does not inhibit amyloid formation by human amylin. (A) Right angle light scattering assays of the time course of amyloid
formation in the absence (black) and in the presence (red) of a 20-fold excess of aspirin. No thioflavin-T was added to either sample. (B) TEM
image of the sample of amylin without aspirin recorded at the end of the kinetic experiment. (C) TEM image of the sample of amylin with a 20-fold
excess aspirin recorded at the end of the kinetic experiment. Scale bars represent 100 nm. Experiments were conducted at pH 7.4 and 25 °C in 20
mM Tris buffer with 0.25% DMSO (v/v) in the absence of any fluorinated alcohol cosolvent. The concentration of amylin was 16 μM, and the
concentration of aspirin was 320 μM.
Figure 4. Aspirin does not disaggregate preformed human amylin amyloid fibrils. (A) Thioflavin-T fluorescence assays of the time course of amyloid
formation. A 20-fold excess of aspirin was added at the time point indicated by the red arrow. (B) TEM image of the sample just before the addition
of a 20-fold excess aspirin (indicated by the black star). (C) TEM image of the sample just after the addition of a 20-fold excess aspirin (indicated by
the green star). (D) TEM image of the sample 48 h after the addition of 20-fold excess aspirin (indicated by the blue star). Scale bars represent 100
nm. Experiments were conducted at pH 7.4 and 25 °C in 20 mM Tris buffer with 0.25% DMSO (v/v) in the absence of any fluorinated alcohol
cosolvent. The concentration of amylin was 16 μM, and the concentration of aspirin was 320 μM.
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the absorbance of aspirin and ketoprofen in the range of 200−
250 nm can interfere with CD measurements. We employed
different conditions to induce amyloid formation here and
observed no change in the shape of the CD spectrum upon the
addition of aspirin to preformed amyloid fibrils. Congo red
binding was also used to test for the presence of amyloid in the
original studies. Congo red staining is a classic method to probe
amyloid formation, particularly for ex vivo amyloid deposits, and
usually involves monitoring birefringence, but the absorbance-
based assays are also employed. In either case, the dye is an
extrinsic probe, and it has been shown that it is not amyloid
specific.30 In the case of absorbance assays, addition of
compounds can interfere by contributing background absorb-
ance or by interfering with the binding of the dye. These
considerations and the data presented here highlight the
importance of using multiple probes to study amyloid
inhibition, particularly methods such as TEM, which directly
detect amyloid fibrils.
■ METHODS
Peptide Synthesis and Purification. Human amylin was
synthesized on a 0.1 mmol scale using a CEM Liberty microwave
peptide synthesizer utilizing Fmoc chemistry. Solvents used were ACS-
grade. The methods have been described previously.31,32 In order to
afford a peptide with an amidated C-terminus, 5-(4′-fmoc-amino-
methyl-3′,5-dimethoxyphenol) valeric acid (Fmoc-PAL-PEG-PS) resin
was used and purchased from Life Technologies. Standard Fmoc
reaction cycles were used. Fmoc-protected pseudoproline dipeptide
derivatives were incorporated at positions 9−10, 19−20, and 27−28 to
facilitate the synthesis. The β-branched residues, Arg, and all
pseudoproline dipeptide derivatives were double-coupled. A maximum
temperature of 50 °C was used for the coupling of His and Cys in
order to reduce the possibility of racemization. Peptides were cleaved
from the resin by standard trifluoroacetic acid (TFA) methods;
ethanedithiol, thioanosole, and anisole were used as scavengers. Crude
peptides were partially dissolved in 20% acetic acid (v/v), frozen in
liquid nitrogen, and lyophilized to increase their solubility. The dry
peptide was redissolved in 100% dimethyl sulfoxide (DMSO) at room
temperature to promote the formation of the disulfide bond.33,34
Peptides were purified by reverse-phase HPLC using a Proto 300 C18
preparative column (10 mm × 250 mm). A two-buffer gradient was
used: buffer A consisted of 100% H2O and 0.045% HCl (v/v) and
buffer B included 80% acetonitrile, 20% H2O, and 0.045% HCl. HCl
was used as the counterion instead of TFA because residual TFA can
influence amyloid formation. MALDI-TOF mass spectrometry
confirmed the correct molecular weight (expected, 3903.3 Da;
observed, 3902.8 Da).
Sample Preparation. Human amylin was first dissolved in 100%
HFIP at a concentration of 1.6 mM and then filtered to remove any
preformed amyloid aggregates. For thioflavin-T fluorescence assays,
aliquots were lyophilized and redissolved in 20 mM Tris buffer, pH
7.4, at the desired concentration. Aspirin and ketoprofen were
prepared in 100% DMSO.
Thioflavin-T Fluorescence Assays. Solutions were prepared by
adding 20 mM Tris buffer, pH 7.4, and thioflavin-T to lyophilized dry
peptides for a final peptide concentration of 16 μM. For the studies of
aspirin and ketoprofen, 0.25% DMSO was present in the solution.
Measurements were made at 25 °C using a Beckman Coulter DTX880
plate reader without stirring. An excitation filter of 430 nm and an
emission filter of 485 nm were used. To test the potential
disaggregation activity of aspirin, peptide was first incubated in a
low-binding 96-well plate and monitored using a plate reader to ensure
the formation of amyloid fibrils. Aspirin was added at a 20-fold excess
after amyloid formation.
Right Angle Light Scattering Assays (RALS). Solutions were
prepared by adding 20 mM Tris buffer, pH 7.4, without thioflavin-T to
lyophilized dry peptides for a final peptide concentration of 16 μM.
Experiments were conducted using an Applied Phototechnology
fluorescence spectrophotometer. RALS assays used excitation and
emission wavelengths of 500 nm.
Transmission Electron Microscopy (TEM). TEM was performed
at the Life Science Microscopy Center at Stony Brook University.
Aliquots were removed from the same solutions that were used for the
fluorescence measurements. Five microliters of peptide solution was
placed on carbon-coated Formvar 300 mesh copper grid for 1 min and
then negatively stained by incubation with saturated uranyl acetate for
another 1 min.
Figure 5. Ketoprofen does not inhibit amyloid formation by human amylin. TEM images of samples recorded after incubating amylin with varying
amount of ketoprofen for 42 h. Scale bars represent 100 nm. (A) Amylin alone. (B) Mixture of amylin with a 20-fold excess of ketoprofen. (C)
Mixture of amylin with a 10-fold excess of ketoprofen. (D) Mixture of amylin with a 5-fold excess of ketoprofen. (E) Mixture of amylin with a 2-fold
excess of ketoprofen. (F) Mixture of amylin with an equimolar amount of ketoprofen. Experiments were conducted at pH 7.4 and 25 °C in 20 mM
Tris buffer with 0.25% DMSO (v/v) in the absence of any fluorinated alcohol cosolvent. The concentration of amylin was 16 μM.
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Circular Dichroism (CD) Experiments. CD experiments were
performed using an Applied Photophysics Chirascan circular
dichroism spectrometer. The solutions for the CD experiments were
prepared by diluting the filtered stock peptide solutions into 20 mM
Tris buffer at pH 7.4. The final concentration of peptide was 16 μM in
1% HFIP. Spectra were recorded from 198 to 260 at 1 nm intervals in
a quartz cuvette with a 0.1 cm path length at 25 °C. Data were
averaged from three scans. A background spectrum was subtracted
from the collected data.
■ ASSOCIATED CONTENT
*S Supporting Information
CD spectra of pre-formed amyloid fibrils recorded before the
addition of aspirin, immediately after the addition of aspirin, 1 h
after the addition of aspirin, and 12 h after the addition of
aspirin. This material is available free of charge via the Internet
at http://pubs.acs.org.
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